News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
R&D Navigating the complexities of drug development in hepatolog... In the realm of medical research, liver disease remains a complex and often overlooked field.
News EMA panel endorses AI for MASH clinical trials PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
News Novo Nordisk will file semaglutide for MASH next year Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US
R&D The growing challenge of conducting clinical trials for meta... Liver disease is on the rise around the world, posing a significant health concern.
Patients Exploring the role of pharmacy and self-care in the fight ag... Globally, the incidence of fatty liver disease is increasing at a concerning rate, yet, the solution could be simple.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.